SCHEDULE: Lipella Pharmaceuticals Inc. Executive Updates Ownership Stake in Latest Filing
Ownership Update
Jonathan H. Kaufman, a key executive at Lipella Pharmaceuticals, has updated his beneficial ownership in the company to 212,289 shares, representing 11.7% of the outstanding common stock.
Summary
- This document is an amendment to a Schedule 13D filing by Jonathan H. Kaufman regarding his ownership in Lipella Pharmaceuticals Inc.
- The amendment updates his beneficial ownership to 212,289 shares, which includes 112,352 shares purchased with personal funds and 99,937 shares issuable upon exercise of vested stock options.
- This represents 11.7% of the company's outstanding common stock, based on 1,719,222 shares outstanding as of the date of the amendment.
- The filing confirms that no other changes have been made to the previously reported information, except for the updated ownership details.
Sentiment
Score: 7
Explanation: The document is a routine update of ownership, which is generally neutral. The increased ownership by a key executive could be seen as a positive sign, but it's not a major event.
Positives
- The filing indicates continued active involvement and investment by a key executive in the company.
- The increase in ownership through both direct purchase and stock options suggests confidence in the company's future.
Industry Context
This filing is a routine update of beneficial ownership by a key executive, which is common in publicly traded companies. It provides transparency to investors regarding the ownership structure of the company.
Comparison to Industry Standards
- Schedule 13D filings are standard practice for individuals or groups acquiring more than 5% of a company's voting shares.
- The level of detail provided in this filing is consistent with SEC requirements for such disclosures.
- Similar filings are made by executives and major shareholders in other pharmaceutical companies, such as Pfizer, Moderna, and Johnson & Johnson, when their ownership changes significantly.
Stakeholder Impact
- The updated ownership information provides transparency to shareholders regarding the stake held by a key executive.
- This filing may influence investor perception of the company's leadership and future prospects.
Key Dates
| Date | Description |
|---|---|
| 12/29/2022 | Initial Schedule 13D filing by Jonathan H. Kaufman. |
| 06/21/2023 | Amendment No. 1 to Schedule 13D. |
| 03/06/2024 | Amendment No. 2 to Schedule 13D. |
| 03/15/2024 | Amendment No. 3 to Schedule 13D. |
| 03/19/2024 | Amendment No. 4 to Schedule 13D. |
| 05/06/2024 | Amendment No. 5 to Schedule 13D. |
| 10/17/2024 | Amendment No. 6 to Schedule 13D. |
| 12/27/2024 | Amendment No. 7 to Schedule 13D. |
| 01/03/2025 | Amendment No. 8 to Schedule 13D. |
| 01/17/2025 | Amendment No. 9 to Schedule 13D. |
| 01/21/2025 | Date of event requiring this Schedule 13D filing. |
| 01/23/2025 | Date of signature for this Amendment No. 10. |
Keywords
beneficial ownership, Schedule 13D, Lipella Pharmaceuticals, Jonathan H. Kaufman, stock options, common stock, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.